Artificial intelligence and multiomics integration for Parkinson's disease drug development.

Area of Science:

• Neuroscience
• Computational Biology
• Genetics

Background:

• Parkinson's disease (PD) diagnosis and treatment face limitations due to its complex molecular underpinnings.
• Multi-omics data (genomics, transcriptomics, proteomics, metabolomics) offer a holistic view of PD.
• Artificial intelligence (AI) is crucial for analyzing large, complex biological datasets.

Purpose of the Study:

• To review the potential of integrating multi-omics data with AI for Parkinson's disease research.
• To outline a framework for advancing PD diagnosis, treatment, and drug discovery.
• To highlight the synergy between multi-omics and AI in neurodegenerative disease research.

Main Methods:

• Literature review of recent advances in multi-omics and AI applications in Parkinson's disease.
• Exploration of AI algorithms for processing and integrating multi-omics datasets.
• Discussion of frameworks for applying these technologies to neurodegenerative diseases.

Main Results:

• Integration of multi-omics and AI can provide a comprehensive molecular landscape of Parkinson's disease.
• AI enables efficient processing of extensive multi-omics data for deeper biological insights.
• This integrative approach promises improved early diagnosis and personalized therapeutic strategies.

Conclusions:

• The combination of multi-omics and AI holds transformative potential for Parkinson's disease research.
• This framework can accelerate drug discovery and development for PD.
• It offers a pathway to advance the diagnosis and treatment of neurodegenerative diseases.